A final rule that will change the Medicaid prescription drug reimbursement formula.

Repors examines policy options that would help increase generic drug use and decrease costs for the Medicare prescription drug benefit.

The House later this month is expected to debate reauthorization of the Prescription Drug User Fee Act, which since its passage in 1992 has been a "huge success" in speeding FDA approval times for new prescription drugs, the Washington Post reports. The Senate recently approved a bill (S 1082) that includes a five-year reauthorization of PDUFA.

FDA has granted final approval for Caraco Pharmaceutical's Abbreviated New Drug Application for paroxetine hydrochloride tablets, USP (Paroxetine HCl).

FDA continues to warn the American public about the dangers of buying medications over the Internet.

Research demonstrated the power of new drug technology being developed by Centrose biopharmaceutical start-up, to overcome the increasingly vexing problem of drug resistance.

Actavis Group has launched NIFEdipine extended-release tablets. Distribution of the product will commence immediately.

Ferring Pharmaceuticals has received approval from the U.S. Food and Drug Administration to market ENDOMETRIN (progesterone) Vaginal Insert, 100 mg.

U.S. Food and Drug Administration has cleared for marketing the INRange Systems' Electronic Medication Management Assistant.

SyntheMed has been informed by the US Food and Drug Administration that it will review the Company's Pre-market Approval application for REPEL-CV Adhesion Barrier.

Half of all adults in the U.S. still believe that the FDA is doing a fair or poor job when it comes to ensuring the safety and efficacy of new prescription drugs.

Center for Molecular Medicine is the first Midwest-based laboratory to offer the FDA-approved AmpliChip CYP450 Test to physicians and hospitals.

U.S. Food and Drug Administration has granted final approval for Lupin Pharmaceuticals's Abbreviated New Drug Application for Trandolapril Tablets, 1mg, 2mg and 4mg.

Barr Laboratories announced the dismissal of litigation related to its challenge of the patent protecting Eli Lilly and Company's ZYPREXA Zydis (Olanzapine) Orally Disintegrating Tablets, 5mg, 10mg, 15mg and 20mg.

Hong Kong Department of Health called on members of the public not to buy or use a brand of health product called 'Junyu Jiaonanyihao', which was found to have contained undeclared western drug ingredients that may cause side effects.